TAISHO KAMPO STOMACH MEDICINE "SAWAWA" GRANULES

◆ TAISHO KAMPO STOMACH MEDICINE "Sawawa" GRANULES is a gastrointestinal medicine that combines Anchusan and Shigyakusan, and is developed as prescription for people living in modern society who are exposed to various kinds of stress, and have trouble with their autonomic nervous system. ■ The drug relieves gastrointestinal symptoms such as pain and heaviness in the stomach for those who cannot get rid of stress, and are busy with work and household chores. ■The unique preparation technique has realized a preparation with good aroma and flavor (aromatic stomach herbal medicine is contained).

Indication

The following symptoms may occur in persons with moderate or relatively weak physical strength: occasional dullness in the chest and stomach, anxiety/insomnia/irritation, heavy stomach feeling, feeling of discomfort in the stomach, stomachache, belch, loss of appetite, feeling of stomach/abdominal distention, pressure on the chest, heartburn, chlorhydria, abdominal pain, nausea (queasiness, nausea), neurotic gastritis

Dosage and administration

Take the following dose with cold or lukewarm water before a meal or between meals.

15 years or over: 1 packet per dose, 3 times daily

Under 15 years: Do not take

Comply with the prescribed dosage and administration instructions.

ingredient and amount

In 1 packet (1.4 g)

Anchusan 700mg (equivalent to 200mg of Cinnamon bark, 150mg of Corydalis tuber,150mg of Oyster shell,75mg of Fennel,50mg of Amomum seed,50mg of Glycyrrhiza,25mg of Ryokyo)

Shigyakusan Dry Extract 303.33mg (equivalent to 333.33mg of Bupleurum root, 333.33mg of Immature orange, 333.33mg of Peony root ,166.67mgof Glycyrrhiza)

Excipients

Dextrin, anhydrous silicic acid ,Powdered sugar, cellulose, Hydroxypropylcellulose, Sucralose ,Talc

Precautions relating to ingredient and amount

The drug contains herbal medicine as a raw ingredient. The color of the drug may differ slightly, but this will not affect the efficacy.

Precautions

Consultation

• The following persons should contact a physician, pharmacist, or registered salesperson for a consultation before administration.

Patients undergoing medical treatment from a physician

Pregnant women or women suspected of being pregnant.

Patients who have experienced rash/redness, itching, etc. with drugs, etc.

Persons who is physically weak (declining of physical strength or constitutional weakness)

• If the following symptoms are observed after taking this drug, these may be adverse reactions, so immediately discontinue the use of this drug, and show this document to your physician, pharmacist, or registered salesperson for a consultation.

Skin

rash/redness

itchina

• When symptoms do not improve even after taking this medicine for about 1 week, stop taking this medicine and consult a physician, pharmacist or registered salesperson, being sure to take this instruction leaflet with you.

Precautions for storage and handling

Avoid direct sunlight, and store the product in a cool place with little humidity.

Store the product beyond the reach of children.

Do not transfer the drug to other containers. (It may lead to misuse or quality deterioration)

Do not take the product past the expiration date.

11-Jul-2019 1/2 page

[Disclaimer on Multilingual OTC Product Information]

- •This product is a pharmaceutical product approved under a Japanese law, the Law for Ensuring the Quality, Efficacy and Safety of Drugs and Medical Devices, with a view to its sale and use in Japan.
- •Multilingual product information is a translation of the product labeling written in Japanese and provided for your information only. It does not warrant that its contents and the product itself conforms to laws and regulations in countries other than Japan.
- •Multilingual product information is a tentative translation by the provider (or Our Company), and may be modified or altered without notice.
- •The provider (or Our Company) assumes no responsibility for any occurred problem attributable to the contents of the multilingual product information.

11-Jul-2019 2/2 page